- 1 Title A protocol for a systematic review with prospective individual patient data meta-analysis in
- 2 EGFR mutant NSCLC with brain metastases to assess the effect of SRS + Osimertinib compared to
- 3 Osimertinib alone: the STARLET collaboration.
- 4 Author names
- 5 Dr Kristy P Robledo\*, NHMRC Clinical Trials Centre, University of Sydney, Australia;
- 6 Kristy.robledo@sydney.edu.au
- 7 Dr Shilo Lefresne, BC Cancer Agency, Canada SLefresne@bccancer.bc.ca
- 8 Dr Yu Yang, National University Cancer Institute Singapore, yu yang soon@nuhs.edu.sg
- 9 Dr Arjun Sahgal, Sunnybrook Health Science Centre, Canada, Arjun.Sahgal@sunnybrook.ca
- 10 A/Prof Mark B Pinkham, University of Queensland and Princess Alexandra Hospital, Australia
- 11 Mark.Pinkham@health.qld.gov.au
- 12 Prof Alan Nichol, BC Cancer Agency, Canada, anichol@bccancer.bc.ca
- 13 Dr Ross Andrew Soo, National University Cancer Institute Singapore ross\_soo@nuhs.edu.sg
- 14 Dr Ambika Parmar, Sunnybrook Health Sciences Centre, Canada ambika.parmar@sunnybrook.ca
- 15 Dr Fiona Hegi-Johnson, Peter MacCallum Cancer Centre, Australia Fiona. Hegi-
- 16 Johnson@petermac.org
- 17 Dr Mark Doherty, St Vincents University Hospital, Ireland, <a href="mailto:mdoherty@svcpc.ie">mdoherty@svcpc.ie</a>
- 18 Prof Benjamin J Solomon, Peter MacCallum Cancer Centre, Australia Ben.solomon@petermac.org
- 19 Dr David Shultz, Princess Margaret Cancer Centre, Canada david.shultz@rmp.uhn.ca
- 20 Dr Ivan WK Tham, Mt Elizabeth Novena Hospital, Singapore ivan.tham@ihhhealthcare.com
- 21 Dr Adrian Sacher, Princess Margaret Cancer Centre, Canada Adrian.Sacher@uhn.ca

22 Dr Jeremy Tey, National University Cancer Institute Singapore jeremy tey@nuhs.edu.sg, 23 Dr Cheng Nang Leong, National University Cancer Institute Singapore 24 Cheng Nang Leong@nuhs.edu.sg 25 Dr Wee Yao Koh, National University Cancer Institute Singapore wee\_yao\_koh@nuhs.edu.sg 26 Dr Yiqing Huang, National University Cancer Institute Singapore yiqing\_huang@nuhs.edu.sg 27 Dr Yvonne Ang, National University Cancer Institute Singapore Yvonne ang@nuhs.edu.sg 28 Dr Jiali Low, National University Cancer Institute Singapore Jiali low@nuhs.edu.sg 29 Dr Clement Yong, National University Hospital Singapore clement\_yong@nuhs.edu.sg 30 Dr Mei Chin Lim, National University Hospital Singapore mei chin lim@nuhs.edu.sg 31 Dr Ai Peng Tan, National University Hospital, Singapore, ai peng tan@nuhs.edu.sg 32 A/Prof Chee Khoon Lee, NHMRC Clinical Trials Centre, University of Sydney, Australia 33 chee.lee@sydney.edu.au 34 Dr Cheryl Ho, BC Cancer Agency, Canada, CHo@bccancer.bc.ca 35 On behalf of the oSimertinib with or without sTereotActic Radiosurgery in egfr non-small cell Lung 36 cancEr with brain metastases (STARLET) Collaboration 37 38 \*Corresponding author; Kristy.robledo@sydney.edu.au; 92-94 Parramatta Road, Camperdown, 2050 39 40 Word count 2728 41 Number of figures: 0 42 Number of tables: 1

43 **DECLARATIONS** 44 Ethics approval and consent to participate 45 IPD will be provided by each included trial on the stipulation that ethical approval has been provided 46 by their respective Human Research Ethics Committees (or equivalent), and participants gave 47 informed consent before enrolment. Only trials with ethics approval will be included in these 48 analyses. Trialists remain the custodians of their own data, which will be de-identified before being 49 shared with the Collaboration. 50 Each trial contributing data to this project has been approved by ethics committees. OUTRUN (TROG 51 17.02, NCT03497767) has ethics approval from Melbourne Health Human Research Committee, 52 Melbourne, Australia and LUOSICNS (NCT03769103) has ethics approval from British Columbia 53 Cancer Agency Research Ethics Board, University of British Columbia, Canada. 54 Consent for publication 55 NA 56 Availability of data and materials 57 Data sharing is not applicable to this article as no datasets were generated or analysed during the 58 current study. 59 Competing interests 60 SL: research funding and honoraria from AstraZeneca. 61 YYS: Honoraria: AstraZeneca, Janssen 62 ASah: research grants (Institution) from Elekta AB, Varian, Seagen Inc and BrainLAB. Consulting fees 63 from Varian, Elekta (Gamma Knife Icon), BrainLAB, Merck, Abbvie and Roche. Honoraria: 64 AstraZeneca, Elekta AB, Varian, BrainLAB, Accuray, Seagen Inc.

66

67

69

71

73

74

75

76

77

79

83

84

85

86

87

MBP: speaker fees AZ, BMS, MSD, Roche. AN: research grants from Varian Medical Systems Ltd. RAS: advisory board: Amgen, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, Janssen, Lily, Merck, 68 Merck Serono, Novartis, Pfizer, Puma Biotechnology, Roche, Taiho, Takeda, Thermo Fisher, Yuhan Corporation, research grant: Astra-Zeneca, Boehringer Ingelheim 70 FHJ: clinical trial funding, received honoraria and participated in advisory boards for Astra Zeneca. She has received payments and honoraria from BeiGene and MSD for lectures and presentations. 72 Her work is supported by the Peter Mac Foundation and the Victorian Cancer Agency. BJS: Advisory Board/Honoraria from AstraZeneca, Pfizer, Novartis, Roche, Takeda, Merck, Bristol Mysers Squibb, Janssen, Amgen, Eli Lilly IT: Honorarium Elekta, MSD CH: advisory boards with Abbvie, Amgen, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Jazz, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, research grants: AstraZeneca, EMD Serono, Roche 78 CKL: Advisory board: Amgen, Astra Zeneca, GSK, Merck KGA, Norvatis, Pfizer, Roche, Takeda, Boehringer-Ingelheim, Yuhan. Research Funding (Institution): Astra Zeneca, Roche, Merck KGA, 80 Amgen 81 KR, AP, MD, DS, ASac, JT, CNL, WYK, YH, YA, JL, CY, MCL, and APT have no competing interests. CH, 82 SL, FHJ, CKL, YY, RAS and IT are study chairs on the included trials. **Funding** OUTRUN was supported by the following: Sponsored by Trans Tasman Radiation Oncology Group (TROG) Cancer Research, ESR funding from AstraZeneca, National University Health System (NUHS) Seed Fund, NUHSRO/2019/053/RO5+5/Seed-Mar/06), National University Health System (NUHS) Medical Research Application (HREF) - Cancer Fund, National University Cancer Institute, Singapore

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

(Gift from Mr Sajiv Misra via Phoenix Advisers Pte Ltd), The Royal Australian New Zealand College of Radiologists (RANZCR) Research Grant. LUOSICNS was supported by ESR funding from AstraZeneca. **Authors Contributions** KR, CKL, YY, FHJ, CH, AN and SL conceived the idea for this study. KR, YY, CKL, FHJ, MP, RS, CH, AN and SL developed the research question and protocol registration. KR wrote the first draft of the manuscript. KR and YY developed the eligibility and search strategy, and performed the search and screening. All authors critically reviewed and provided feedback on the intellectual content of the manuscript and agreed and approved the final version. **Acknowledgements** We would like to thank AstraZeneca for their ongoing support of both clinical trials. We would also like to thank Cancer Australia for their support for OUTRUN. YYS: Supported by the National Medical Research Council (NMRC/MOH/000396) **KEYWORDS** Individual participant data meta-analysis, EGFR mutant NSCLC, stereotactic radiosurgery, Osimertinib, brain metastases

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

ABSTRACT: 268/350 words Background: Patients with advanced non-small-cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) gene are a heterogenous population who often develop brain metastases (BM). The optimal management of patients with asymptomatic brain metastases is unclear given the activity of newer generation targeted therapies in the central nervous system. We present a protocol for an individual patient data prospective meta-analysis (IPD-PMA) to evaluate whether the addition of stereotactic radiosurgery (SRS) before Osimertinib treatment will lead to better control of intracranial metastatic disease. This is a clinically relevant question that will inform practice. Methods: Randomised controlled trials (RCTs) will be eligible if they included: participants with BM arising from EGFR mutant NSCLC and suitable to receive Osimertinib both in the first- and secondline settings (P); comparisons of SRS followed by Osimertinib versus Osimertinib alone (I, C); and intracranial disease control included as an endpoint (O). Systematic searches of Medline (Ovid), Embase (Ovid), Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL (EBSCO), PsychInfo, ClinicalTrials.gov and the World Health Organisation's International Clinical Trials Registry Platform's Search Portal will be undertaken. An IPD meta-analysis will be performed using methodologies recommended by the Cochrane Collaboration. The primary outcome is intra-cranial progression free survival, as determined by RANO-BM criteria. Secondary outcomes include overall survival, time to whole brain radiotherapy, quality of life and adverse events of special interest. Effect differences will be explored among pre-specified subgroups. **Ethics and dissemination:** Approved by each trials ethics committee. Results will be relevant to clinicians, researchers, policymakers and patients, and will be disseminated via publications, presentations and media releases. Prospero registration: CRD42022330532

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

Strengths and Limitations of this study The use of an individual patient data (IPD) meta-analysis will give increased statistical power for the relative comparison of SRS followed by Osimertinib versus Osimertinib alone on intracranial progression-free survival. Such a meta-analysis will also enable the exploration of subgroups. Frequency of outcome assessment and outcome measures may be collected and reported differently across included trials, which may lead to some imprecision. Harmonisation of clinical trial protocols through prospective meta-analysis will address some of these limitations. A limitation of this study is that the searches will only be conducted until late 2023 and any studies that are registered after this time will not be included. **Abbreviations** AESI adverse events of special interest ASCO American Society of Clinical Oncology American Society for Radiation Oncology **ASTRO** ВМ brain metastases EGFR epidermal growth factor receptor FDA U.S. Food and Drug Administration Grading of Recommendations Assessment, Development and Evaluation () GRADE ic-PFS intracranial disease progression-free survival IPD individual patient data

155 NSCLC Non-small-cell lung cancer 156 OS overall survival Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 157 PRISMA-P 158 extension for protocols (P) 159 randomised controlled trial RCT 160 SNO Society for Neuro-Oncology 161 SRS Stereotactic radiosurgery 162 STARLET oSimertinib with or without sTereotActic Radiosurgery in egfr non-small cell Lung 163 cancEr with brain metastases 164 tyrosine kinase inhibitors TKI 165 166 167 168 169 170 171 172 173 174 175

#### INTRODUCTION

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

Non-small-cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) gene is a distinct subtype that is characterised by a high tumour response rate when treated with small molecule EGFR tyrosine kinase inhibitors (TKIs), Approximately 20% to 40% of patients with advanced NSCLC will develop brain metastases (BM) at some point during their disease course, and it is possible that patients with EGFR mutant NSCLC at greater risk due to improved survival (1, 2). Stereotactic radiosurgery (SRS) involves the precise delivery of high doses of ionising radiation over a single or limited number of fractions to an intracranial target (3). Based on populations with BM from predominantly NSCLC but not enriched for EGFR, incorporating SRS in the management of BM was associated with improvement in overall survival (OS) for those with a single lesion and prolongation of functional independence in those with up to 3 BM (4). However, the detrimental effects of whole brain radiation are now well known such that SRS alone has become the standard of care. Use of SRS alone for multiple BM has been adopted routinely (5), in particular, given the prospective Japanese observational study involving patients with up to 10 BM demonstrated that OS of patients with 5-10 brain metastases treated with SRS alone was non-inferior to those with 2-4 brain metastases (6). Hence for patients with a good performance status, the American Society for Radiation Oncology (ASTRO) strongly recommends SRS for those with 1 to 4 BM and also conditionally recommends this treatment for those with 5 to 10 BM (7). Osimertinib is an oral 3rd generation irreversible mutant selective, wild type sparing EGFR TKI with a higher central nervous system penetration and intracranial activity than first-generation EGFR TKIs. It has been approved by the U.S. Food and Drug Administration (FDA) as a first line treatment for EGFR mutant NSCLC based on the FLAURA trial(8, 9), as well as second line treatment for those who have developed a T790M mutation after exposure to first generation EGFR TKI based on the AURA 3 trial (10). In subset analyses, patients with stable, asymptomatic BM had significantly prolonged

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

intracranial disease progression-free survival (ic-PFS) with Osimertinib compared to Geftinib or Erlotinib in the FLAURA trial (11) and platinum-pemetrexed in the AURA3 trial (12). However, the true intracranial activity of Osimertinib remains unclear as a significant number of patients enrolled in these trials had prior cranial radiotherapy (24% in FLAURA and 41% in AURA3). Notably, the OCEAN trial, a single arm phase two study of with T790M positive EGFR mutant NSCLC and untreated BM, found the intracranial response rate for second line Osimertinib was 67% and median ic-PFS was 25 months (13). Currently, the optimal sequencing of SRS and Osimertinib in patients with EGFR mutant NSCLC and untreated BM is unclear. The American Society of Clinical Oncology (ASCO)- Society for Neuro-Oncology (SNO)-ASTRO guideline states that local therapy may be delayed in selective patients with asymptomatic BM from EGFR mutant NSCLC, however the strength of the recommendation is weak as the quality of evidence supporting this recommendation is low (14). There is conflicting evidence from retrospective cohort studies. Magnuson and colleagues found that those who received upfront cranial irradiation had longer OS than those who received upfront first-generation EGFR TKI with deferred cranial irradiation (15). Similarly, Yu and colleagues observed that upfront cranial radiotherapy was associated with reduced cumulative incidence of ic-PFS in the entire cohort receiving Osimertinib and improvement in OS in a subset of patients with 1-3 BM (16). However, Thomas and colleagues did not find any improvement (17). Two phase II randomised controlled trials (RCTs), OUTRUN (TROG 17.02) (18) and LUOSICNS (19) are independently recruiting participants with BM from EGFR mutant NSCLC to evaluate whether SRS followed by Osimertinib is more efficacious than Osimertinib alone in delaying progression of intracranial disease. OUTRUN completed recruitment in September 2022, and LUOSICNS completed recruitment in April 2023. Both have a sample size of 40 participants, and individually lack the statistical power to formally compare differences between treatment arms. They are hypothesisgenerating to inform planning of a future definitive phase III RCT.

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

Trial participants

Therefore, we have developed a collaboration, STARLET (oSimertinib with or without sTereotActic Radiosurgery in egfr non-small cell Lung cancEr with brain metastases), to prospectively conduct an individual patient data (IPD) meta-analysis of these RCTs to compare the effects of SRS followed by Osimertinib versus Osimertinib alone followed by deferred local cranial therapies on intracranial disease control in patients with BM from EGFR mutant NSCLC. The purpose is to establish which treatment strategy will lead to better control of intracranial disease, and if there are subgroups of patients that might benefit more from the combination treatment strategies. **METHODS AND ANALYSIS** A systematic review and IPD meta-analysis will be conducted according to the recommended methods (20, 21). Lead investigators of eligible RCTs will be invited to share their IPD and join this STARLET collaboration. Online supplementary Appendix 1 lists eligible RCTs identified up to July 2022. This protocol adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) extension for protocols (PRISMA-P, checklist detailed in supplementary Appendix 2) (22) and has been registered on PROSPERO (CRD42022330532). If subsequent potentially eligible RCTs are published, a nested prospective meta-analysis may be used, in order to combine retrospective inclusion of these additional trials with the proposed results gained from these analyses. At this time, there are no consumers actively involved with the collaboration. Eligibility criteria Types of studies STARLET will include RCTs only. Randomisation may occur at the individual level or by cluster and quasi-randomised trials will be excluded. There are no language or date restrictions.

Participants will be eligible if they are receiving Osimertinib in the first- or second-line setting. For those receiving Osimertinib as first line systemic therapy, all newly diagnosed participants must have a documented sensitising EGFR mutation (including exon 19 del, L858R (exon 21), G719X (exon 18), L861G (exon 21), S768I (exon 20) and T790M (exon 20)) and intracranial metastasis, with or without extracranial disease. For those receiving Osimertinib as second line systemic therapy, participants will have developed intracranial metastases while on first-line 1st or 2nd generation EGFR TKI therapy, with no or stable extracranial disease regardless of T790M mutation. Intracranial disease is defined as: (a)  $\leq$  10 lesions visible and measurable on protocol screening MRI, with at least one BM amenable to SRS; (b) no single BM exceeding 30mm in longest diameter; and (c) absence of neurologic symptoms except for headache, nausea or seizure which were medically controlled. Interventions One intervention is SRS followed by Osimertinib. The SRS dose-fractionation schedule depends on size and location of the lesion. The SRS is to be planned after randomisation, and Osimertinib commences after the completion of SRS. Osimertinib treatment is described below. The other intervention is Osimertinib alone. Osimertinib will be administered orally as one 80 mg tablet once a day. A cycle of treatment is defined as 28 days of once daily Osimertinib treatment. For those allocated to Osimertinib alone, treatment with Osimertinib will commence following randomisation. Participants may continue to receive treatment with Osimertinib as long as they are continuing to show clinical benefit, as judged by the treating clinician, and within the guidelines of the relevant trial protocol's discontinuation criteria.

Information sources and search strategy

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

We searched the following databases from their inception: Medline (Ovid), Embase (Ovid), Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL (EBSCO), PsychInfo, ClinicalTrials.gov and the World Health Organisation's International Clinical Trials Registry Platform's Search Portal. The full search strategy is available in Online Supplementary Appendix 2. The initial search was completed up to July 2022, and will be updated regularly to search for new trials until late-2023. Collaborators and contacts were asked to notify us of any additional planned, or ongoing completed trials that may fulfil eligibility criteria. At this time, only the two aforementioned trials (OUTRUN, TROG 17.02: NCT03497767 and LUOSICNS: NCT03769103) have been identified, and both trial teams have agreed to share IPD for this collaboration. Selection of studies for inclusion in the review Two members of the STARLET Collaboration will independently screen all future retrieved records against eligibility criteria. Any discrepancies will be resolved by consensus or, if required, adjudication by a third reviewer. The Principal Investigator and/or corresponding author of any additional eligible studies will be invited to join the STARLET Collaboration. If there is no response to initial emails, we will contact other co-authors or contacts listed on registration records. If IPD are not available for an eligible trial, we will use aggregate data where possible. Data collection, management, and confidentiality Data receipt / extraction De-identified IPD will be shared via secure data transfer platforms or via institutional secure email using password-protected zip files. Data will be provided according to a pre-specified coding template where possible, otherwise, data will be accepted in any format and recoded as necessary. The data management team will receive and store the data in perpetuity in a secure, customised database at the NHMRC Clinical Trials Centre, University of Sydney, and data management will

follow the University of Sydney's Data Management Policies. Each trial team will also be asked to provide metadata (such as questionnaires, data collection forms, and data dictionaries) to aid understanding of the datasets. Trial-level data, such as intervention details (setting, timing and duration), intervention details, method of sequence generation, allocation concealment, geographical location, sample size, outcome measures and definitions will be cross-checked against published reports, trial protocols, registration records and data collection sheets, in order to ensure data integrity.

### Data processing

IPD from each trial will be checked with respect to range, internal consistency, consistency with published reports and missing items. Integrity of the randomisation process will be examined by reviewing the chronological randomisation sequence and pattern of assignment, as well as the balance of participant characteristics across intervention and control groups. Any inconsistencies or missing data will be discussed with trialists/data managers and resolved by consensus. Each included trial will be analysed individually, and results shared with trialists for verification. Once finalised, data from each of the trials will be combined into a single database.

## Risk of bias assessment and certainty of evidence appraisal

Included studies will be assessed for risk of bias by two reviewers, independently, using the criteria described in the Cochrane handbook (23): random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and other bias. The quality of evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (24). Any differences will be resolved by consensus or with a third reviewer.

## **Primary outcome**

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

The primary outcome will be ic-PFS at 12 months, as determined by RANO-BM criteria (25). Secondary outcomes All outcomes and their definitions are detailed in Table 1. Secondary outcomes include OS, time to whole brain radiotherapy, quality of life and adverse events of special interest (AESI). Covariates and subgroups Individual and study-level subgroup analyses will be conducted for ic-PFS. Individual-level characteristics to be assessed include mutation type (EGFR exon19 deletion vs exon 21 L858R vs uncommon sensitising mutations, pending numbers), line of therapy (first vs second), number of BM (either: <4 vs  $\ge 4$  or 1 vs  $\ge 2$ , pending total numbers), diameter of largest lesion ( $\le 15$ mm vs >15mm), age at baseline (<70 vs ≥70 years), sex (male vs female), country of treatment (Singapore vs Australia vs Canada), ethnicity (Asian vs other), smoker (never vs ex or current smoker), extracranial disease presence at baseline (present vs absent), and ECOG performance status (0 vs ≥1). If data are insufficient for the pre-specified subgroup analyses, categories will be reassessed prior to any analyses, by consensus of the STARLET collaboration. Data analysis A detailed statistical analysis plan will be prepared and agreed on by the STARLET Collaboration members prior to any analyses being undertaken. Analyses will include all randomised participants who meet the inclusion criteria, for which IPD are available. All analyses will be based on randomised treatment allocation (intention to treat principle). For the primary outcome of ic-PFS at 12 months, cumulative incidence estimates taking into account the competing risk of extracranial progression (with their variances) from the trials will be pooled using inverse variance weighting (two stage approach). Other secondary outcomes will be examined using Cox regression or linear models, adjusted for study (one stage approach). Heterogeneity of

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

treatment effects across trials will be estimated using I<sup>2</sup>, and investigated by fitting a trial-bytreatment interaction term to the models. Any heterogeneity identified will be explored further. Differences in treatment effect between the pre-specified subgroups will be examined by testing a treatment by subgroup interaction term within a Fine-Gray regression model for ic-PFS, taking into account competing risks. Findings of subgroup analyses will be reported as exploratory. Missing data may be explored in sensitivity analyses using multiple imputation. Analyses will be performed using SAS and the open-source software R (26). Assessment of selection or publication bias Potential selection bias and publication bias may be investigated by conducting a nested prospective meta-analysis and comparing trials that were included prospectively versus those identified retrospectively in a sensitivity analysis (if appropriate). Contour-enhanced funnel plots to examine whether there are differences in results between more and less precise studies. Adjustments for multiple testing No formal adjustments will be made for multiple comparisons. However, we will follow Schulz and Grimes' approach (27) and interpret the patterns and consistency of results across related outcomes rather than focusing on statistical significance alone. Planned sensitivity analyses If possible, the following sensitivity analyses will be conducted for the primary outcome; including published aggregate data combined with IPD in the meta-analysis compared to IPD alone and including prospectively included trials only. Additional sensitivity analyses may be conducted on other outcomes to determine the effect of missing data. These will be detailed in the statistical analysis plan.

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

**Project management** Membership of the STARLET Collaboration includes representatives from each of the trials contributing IPD to the project. Trial representatives have the opportunity to contribute their expert knowledge to the Collaboration and provide input into the protocols, statistical analysis plan, and final results manuscript. The STARLET Collaboration will be responsible for data collection, management and analysis, as well as communication within the Collaboration, including organisation of virtual or face-to-face collaborator meetings. **ETHICS AND DISSEMINATION Ethical considerations** IPD will be provided by each included trial on the stipulation that ethical approval has been provided by their respective Human Research Ethics Committees (or equivalent), and participants gave informed consent before enrolment. Only trials with ethics approval will be included in these analyses. Trialists remain the custodians of their own data, which will be de-identified before being shared with the Collaboration. Publication policy Manuscripts will be prepared by the relevant members of the STARLET Collaboration, and circulated for comment, revision and approval prior to submission for publication. Any reports of the results from this study will be published either in the name of the collaborative group, or by representatives of the collaborative group on behalf of the STARLET Collaboration, as agreed by all members.

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

DISCUSSION An IPD meta-analysis is considered the gold standard of systematic reviews, and has many advantages over a standard aggregate approach. This includes the collaboration of a range of expert trialists and biostatisticians in order to ensure that all possible RCTs are included and appropriate analysis of outcomes are performed. Through prospectively collaborating, STARLET can pre-specify the patient population, interventions, and outcomes clearly and harmonise trial protocols where possible. Another clear advantage is the increase in statistical power. The two eligible RCTs identified at this time are both Phase II RCTs that individually are not powered to identify a statistically significant difference between treatments, but rather are looking for efficacy signals and safety of treatment. We will seek to address this with the use of a prospective meta-analysis to include published aggregate data, and by encouraging planned and ongoing trials to collect our core outcomes and share data. Based on the recruitment timelines of the two trials identified, we plan to complete study identification by end of 2023, IPD collection by mid-2024 and conduct the analyses and disseminate the results by mid-2025. These timelines may be adjusted if follow-up completes early, or if additional trials are identified and not completed in time to provide data. The results of this systematic review will guide whether a Phase III study is required to inform clinical practice, and, if so, may help investigators to pre-plan subgroup analyses of interest.

# **REFERENCES** 1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. Journal of clinical oncology. 2004;22(14):2865-72. 2. Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88(1):108-11. 3. Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL. Current approaches to the management of brain metastases. Nature Reviews Clinical Oncology. 2020;17(5):279-99. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain 4. radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. The Lancet. 2004;363(9422):1665-72. 5. Sahgal A, Ruschin M, Ma L, Verbakel W, Larson D, Brown PD. Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issues. Neuro Oncol. 2017;19(suppl\_2):ii2-ii15. 6. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387-95. 7. Gondi V, Bauman G, Bradfield L, Burri SH, Cabrera AR, Cunningham DA, et al. Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology. 2022;12(4):265-82. 8. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival

2020;382(1):41-50.

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434


435


436

437

438

with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med.





## Table 1: Outcomes for individual patient data meta-analysis

Outcome	Definition
Primary outcome	
Intracranial progression free	Time from randomisation to intracranial disease
survival (iPFS) at 12 months	progression, as defined according to RAN-NO
Secondary outcomes	
PFS	Time from randomization to any disease progression
Overall survival	Time from randomization to death
Time to salvage whole brain	Time from randomization to salvage whole brain
radiotherapy	radiotherapy
Time to salvage SRS	Time from randomization to salvage stereotactic
	radiotherapy
time to local brain failure	Time from randomization to local brain failure
time to distant progression	Time from randomization to distant disease progression
QOL	QLQ-C30
	QLQ-BN 20
Adverse events of special interest	Rates of the following AE (for example): radiation necrosis,
	neurocognitive impairment, edema cerebral, muscle
	weakness right side, muscle weakness left side, Fatigue,
	Gait disturbance, Headache, Seizures, Tremors, Lethargy,
	Dizziness, Syncope, Stroke and Intracranial hemorrhage